Ligand validation:6GA9

TRD: TRIDECANE

TRD is a Ligand Of Interest in 6GA9 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6GA9_TRD_A_303	29%	77%	0.134	0.788	0.12	0.79	-	-	1	0	100%	1
5H2J_TRD_A_601	2%	71%	0.272	0.55	0.3	0.8	-	-	0	0	100%	1
5H2O_TRD_A_601	2%	71%	0.271	0.541	0.3	0.8	-	-	0	0	100%	1
5H2N_TRD_A_601	2%	71%	0.22	0.485	0.3	0.8	-	-	0	0	100%	1
5H2M_TRD_A_601	2%	71%	0.227	0.488	0.3	0.8	-	-	0	0	100%	1
5H2L_TRD_A_601	2%	71%	0.251	0.51	0.3	0.8	-	-	0	0	100%	1
4ZR1_TRD_A_410	49%	75%	0.18	0.926	0.12	0.84	-	-	1	0	100%	1
6PW0_TRD_D_303	43%	75%	0.148	0.927	0.12	0.85	-	-	0	0	69%	0.6923
6PW1_TRD_D_301	42%	76%	0.141	0.913	0.12	0.81	-	-	0	0	69%	0.6923
6LPK_TRD_A_2422	41%	98%	0.14	0.853	0.14	0.14	-	-	0	0	100%	1
2GSM_TRD_A_5007	41%	85%	0.15	0.862	0.22	0.51	-	-	2	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.